<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN"  
  "http://www.w3.org/TR/html4/loose.dtd">  
<html > 
<head><title>UCI AP Controller Project Proposal</title> 
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1"> 
<meta name="generator" content="TeX4ht (http://www.tug.org/tex4ht/)"> 
<meta name="originator" content="TeX4ht (http://www.tug.org/tex4ht/)"> 
<!-- html --> 
<meta name="src" content="Project_Proposal.tex"> 
<link rel="stylesheet" type="text/css" href="Project_Proposal.css"> 
</head><body 
>
   <div class="maketitle">



<h2 class="titleHead">UCI AP Controller Project Proposal</h2>
 <div class="author" ><span 
class="cmr-12">Mike Sutherland</span></div><br />
<div class="date" ><span 
class="cmr-12">January 7, 2020</span></div>
   </div> <div 
class="abstract" 
>
<div class="center" 
>
<!--l. 23--><p class="noindent" >
<!--l. 23--><p class="noindent" ><span 
class="cmbx-9">Summary</span></div>
     <!--l. 24--><p class="indent" >    <span 
class="cmr-9">An automatic insulin dosing mechanism composed of an insulin pump,</span>
     <span 
class="cmr-9">continuous  glucose  monitor  (CGM),  and  dose  controller,  is  close  to  a</span>
     <span 
class="cmr-9">mechanical cure for Type 1 diabetes. The dose controller is an integral</span>
     <span 
class="cmr-9">part  of  the  system,  and  can  be  designed  using  a  range  of  techniques</span>
     <span 
class="cmr-9">from the field of control systems engineering. The AP controller project</span>
     <span 
class="cmr-9">proposed here would be to research, design, and test dose controllers on</span>
     <span 
class="cmr-9">virtual patients. If software testing is successful, the controller can be</span>
     <span 
class="cmr-9">implemented cheaply in hardware as a proof of concept.</span>
</div>
   <h3 class="sectionHead"><span class="titlemark">1   </span> <a 
 id="x1-10001"></a>Background</h3>
<!--l. 27--><p class="noindent" >
   <h4 class="subsectionHead"><span class="titlemark">1.1   </span> <a 
 id="x1-20001.1"></a>Type 1 Diabetes</h4>
<!--l. 28--><p class="noindent" >Type 1 diabetes is an autoimmune disease which causes the destruction of insulin
producing cells in the body. In healthy people, these insulin-producing cells regulate
blood glucose levels. People with type 1 diabetes must manually regulate their blood
glucose level. Variations in blood glucose result in a variety of adverse physical and
mental effects; management of blood glucose is therefore the principal challenge of
type 1 diabetes.

<!--l. 29--><p class="indent" >   Continuous glucose monitors (CGMs) have enabled automated, high frequency,
real-time readings of blood glucose levels. To dose insulin, people with type 1
diabetes use either imprecise manual injections via syringe, or precise dosing via
insulin pump. Dosing insulin to regulate blood glucose levels is currently a manual
process.
   <h4 class="subsectionHead"><span class="titlemark">1.2   </span> <a 
 id="x1-30001.2"></a>Closed Loop Systems</h4>
<!--l. 31--><p class="noindent" >The combination of a CGM, an insulin pump, and an automated dose controller is
known as a &#8221;Closed Loop System.&#8221; Such systems have historically been limited by
the imprecision of blood glucose measurement, but they are increasingly viable as
sensor technology improves. The logic of the automated dose controller is often
referred to as an AP or AP controller, standing for artificial pancreas.
<!--l. 32--><p class="indent" >   The sensors, infusion sites, and devices required for a closed-loop system are
inconvenient, but they enable a functional cure not yet available through biological
methods.
   <h3 class="sectionHead"><span class="titlemark">2   </span> <a 
 id="x1-40002"></a>Project Goal</h3>
<!--l. 34--><p class="noindent" >The AP Controller project is to implement and test one or more viable insulin dose
controller schemes, which would robustly manage blood glucose under a wide variety
of intrinsic and external conditions. Intrinsic conditions are differences in insulin
resistance and glucose response between patients. External conditions are manual
dosing, arbitrary glucose variations caused by meals or exercise, and missed or
miscalibrated sensor readings.
   <h4 class="subsectionHead"><span class="titlemark">2.1   </span> <a 
 id="x1-50002.1"></a>Project Phases</h4>
<!--l. 36--><p class="noindent" >The project will be split into three phases. The first phase will be to implement the
software patients and a set of comprehensive tests, from which the performance of
the control schemes can be compared. The second phase will be to implement and
test control schemes in software. The third phase will be to implement the control
schemes into hardware. A summary of the higher-order goals is shown in
table&#x00A0;1.
   <div class="table">

<!--l. 40--><p class="indent" >   <a 
 id="x1-50011"></a><hr class="float"><div class="float" 
>

<dl class="list1"><dt class="list">
</dt><dd 
class="list">
<!--l. 41--><p class="noindent" >
<br /><div class="caption" 
><span class="id">Table&#x00A0;1: </span><span  
class="content">Project Phases</span></div><!--tex4ht:label?: x1-50011 -->

<table id="TBL-4" class="tabular" 
cellspacing="0" cellpadding="0"  
><colgroup id="TBL-4-1g"><col 
id="TBL-4-1"><col 
id="TBL-4-2"><col 
id="TBL-4-3"></colgroup><tr  
 style="vertical-align:baseline;" id="TBL-4-1-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-1-1"  
class="td11"> Phase         </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-1-2"  
class="td11"> <!--l. 76--><p class="noindent" >Goal                                                                        </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-1-3"  
class="td11"> <!--l. 76--><p class="noindent" >Category              </td>

</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-2-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-2-1"  
class="td11"> Preliminary  </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-3-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-3-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-3-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;Faculty advisor recruitment                                   </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-3-3"  
class="td11"> <!--l. 76--><p class="noindent" >admin                  </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-4-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-4-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-4-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;Student recruitment                                             </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-4-3"  
class="td11"> <!--l. 76--><p class="noindent" >admin                  </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-5-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-5-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-5-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;Finalized Winter &#8217;20 Roadmap                               </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-5-3"  
class="td11"> <!--l. 76--><p class="noindent" >admin                  </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-6-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-6-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-6-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;<span 
class="cmbx-10">Product:  Project  Proposal  and  Winter  &#8217;19</span>
  <span 
class="cmbx-10">roadmap</span>                                                        </td>

</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-7-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-7-1"  
class="td11"> Phase 1       </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-8-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-8-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-8-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;Implement   &#8221;no   controller&#8221;   test   case   in   patient
  simulator                                                                  </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-8-3"  
class="td11"> <!--l. 76--><p class="noindent" >software               </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-9-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-9-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-9-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;Implement benchmarks for control schemes               </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-9-3"  
class="td11"> <!--l. 76--><p class="noindent" >software, bio-eng    </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-10-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-10-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-10-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;<span 
class="cmbx-10">Product: Phase 1 Design Report</span>                   </td>

</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-11-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-11-1"  
class="td11"> Phase 2       </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-12-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-12-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-12-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;Review literature re: control schemes                       </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-12-3"  
class="td11"> <!--l. 76--><p class="noindent" >control, bio-eng     </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-13-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-13-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-13-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;Implement control scheme                                     </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-13-3"  
class="td11"> <!--l. 76--><p class="noindent" >software               </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-14-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-14-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-14-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;Benchmark and compare control scheme(s)               </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-14-3"  
class="td11"> <!--l. 76--><p class="noindent" >control, bio-eng     </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-15-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-15-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-15-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;Alter control schemes, test                                     </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-15-3"  
class="td11"> <!--l. 76--><p class="noindent" >control, bio-eng     </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-16-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-16-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-16-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;Fundraising for hardware                                       </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-16-3"  
class="td11"> <!--l. 76--><p class="noindent" >admin                  </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-17-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-17-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-17-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;<span 
class="cmbx-10">Product: Phase 2 Design report</span>                     </td>

</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-18-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-18-1"  
class="td11"> Phase 3       </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-19-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-19-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-19-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;Obtain hardware                                                 </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-19-3"  
class="td11"> <!--l. 76--><p class="noindent" >admin                  </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-20-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-20-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-20-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;Develop hardware testing (response simulated)          </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-20-3"  
class="td11"> <!--l. 76--><p class="noindent" >hardware              </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-21-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-21-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-21-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;Port control scheme(s) to hardware                         </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-21-3"  
class="td11"> <!--l. 76--><p class="noindent" >software               </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-22-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-22-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-22-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;Test control schemes in hardware                            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-22-3"  
class="td11"> <!--l. 76--><p class="noindent" >control, software    </td>
</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-23-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-23-1"  
class="td11">            </td><td  style="white-space:wrap; text-align:left;" id="TBL-4-23-2"  
class="td11"> <!--l. 76--><p class="noindent" >&#x00A0;&#x00A0;<span 
class="cmsy-10">&#x2219;</span>&#x00A0;&#x00A0;<span 
class="cmbx-10">Product: Phase 3 Design Report</span>                   </td>

</tr><tr  
 style="vertical-align:baseline;" id="TBL-4-24-"><td  style="white-space:nowrap; text-align:left;" id="TBL-4-24-1"  
class="td11">            </td></tr></table></dd></dl>

   </div><hr class="endfloat" />
   </div>
<!--l. 80--><p class="indent" >   The number of students in the project will determine the timeline of these phases.
With just one student: phase 1 could be completed by mid-winter 2020; phase 2
by mid-spring 2020; and the final phase by end of spring into summer of
2020.
<!--l. 81--><p class="indent" >   Additional students with additional skills would help not only accelerate the
timeline but also expand its scope. More models could be compared and more
robustly tested. Once the test apparatus is in place, the work could be made parallel
&#8211; each student could implement their own controller, and then those controllers could
be tested against one another.
   <h3 class="sectionHead"><span class="titlemark">3   </span> <a 
 id="x1-60003"></a>Approach</h3>
<!--l. 83--><p class="noindent" >
   <h4 class="subsectionHead"><span class="titlemark">3.1   </span> <a 
 id="x1-70003.1"></a>Software Patients and Testing</h4>
<!--l. 84--><p class="noindent" >We will use the FDA approved software simulator, UVA/Padova [4]. A 30-patient (10
adults, 10 children, 10 elderly) version of the simulator is freely available as a python
library called simGlucose [7]. Therefore, the codebase of the project will be written
primarily in Python 3.
<!--l. 85--><p class="indent" >   Benchmarking will be composed of an evaluation of the simulation data after a
long simulated test period (24 - 48 hours). Benchmarks for controller performance
will need to be devised; possibilities include total time in acceptable range,
severity of hypoglycemic events, severity of hyperglycemic events, stability
of blood glucose. Models will be scored based on a combination of these
factors.
<!--l. 86--><p class="indent" >   CGM noise, missed readings, exogenous changes to blood glucose, and
changes to insulin sensitivity can be simulated to test the stability of the
controller.
   <h4 class="subsectionHead"><span class="titlemark">3.2   </span> <a 
 id="x1-80003.2"></a>Controllers</h4>
<!--l. 88--><p class="noindent" >Controllers in closed-loop systems generally fall into two classes: Model Predictive
(MPC) and Proportional-Integral-Derivative (PID) controllers. While PID controllers
are simpler, MPC controllers have yielded the most promising results in
the field. A range of different schemes have been clinically tested &#8211; MPC,
PID, and some hybrids. And many more have been tested in software. [3,
1]
<!--l. 89--><p class="indent" >   As a first stage (phase 2), we will implement an already-existing MPC
controller. At later stages, we will improve the controller to better suit the AP
problem.

   <h4 class="subsectionHead"><span class="titlemark">3.3   </span> <a 
 id="x1-90003.3"></a>Hardware System and Testing</h4>
<!--l. 91--><p class="noindent" >Experimenting with controllers using commercial hardware is
typically not possible. However, some older model Medtronic
pumps<span class="footnote-mark"><a 
href="Project_Proposal2.html#fn1x0"><sup class="textsuperscript">1</sup></a></span><a 
 id="x1-9001f1"></a>
have been reverse-engineered to be controlled using a 915MHz radio module, which is
available from several different manufacturers. The controller itself can run on a
Raspberry Pi Zero WH. The pump/controller interface is available under an MIT
license from the OpenAPS project [5]. It is also written in Python 3. The pump,
radio, and controller hardware are inexpensive, and a complete kit can be purchased
for a student budget (under $1000).
<!--l. 92--><p class="indent" >   Implementing the scheme in hardware, rather than solely in software, is
attractive. Since the AP would be a wearable device, implementing as much of it in
hardware as possible would provide another important engineering constraint for the
model &#8211; power, because the complexity of the controller will have direct implications
on power usage. Further, it provides a real &#8220;proof-of-concept,&#8221; a tangible final
milestone.
   <h3 class="sectionHead"><span class="titlemark">4   </span> <a 
 id="x1-100004"></a>ABET Student Outcomes</h3>
<!--l. 94--><p class="noindent" >This project is compatible with the ABET student outcomes:
<!--l. 96--><p class="indent" >   <span 
class="cmti-10">A. an ability to identify, formulate, and solve complex engineering problems by</span>
<span 
class="cmti-10">applying principles of engineering, science, and mathematics</span>
<!--l. 98--><p class="indent" >   The process of selecting and designing a controller for an AP will present a
significant engineering challenge. The constraints of the AP problem are unique and
will require a solid understanding of control theory and programming. A biological
understanding of the response of blood glucose to insulin and environmental factors
will be required. Finally, designing the hardware interfaces &#8211; particularly the
hardware interface with the software patient model &#8211; will be an additional challenge.
<!--l. 100--><p class="indent" >   <span 
class="cmti-10">B. an ability to apply engineering design to produce solutions that meet specified</span>
<span 
class="cmti-10">needs with consideration of public health, safety, and welfare, as well as global,</span>
<span 
class="cmti-10">cultural, social, environmental, and economic factors</span>
<!--l. 102--><p class="indent" >   Incidence of Type 1 is increasing throughout the developed word for unclear
reasons. The disease affects 1.25 million people in the United States, many of them
children. [2, 6] A full closed-loop AP system is the cutting edge of diabetes care &#8211; for
now, the closest we have to a cure. An robust AP controller is an essential
piece.

<!--l. 103--><p class="indent" >   Also, any medication which can be mechanically delivered and the effects thereof
measured on a continuous basis can be controlled in a similar manner. The design
(interface between delivery and measurement device) and constraints (incomplete
measurements, non-recoverable delivery) of the AP system may partially be shared
by other medications in other contexts.
<!--l. 105--><p class="indent" >   <span 
class="cmti-10">C. an ability to communicate effectively with a range of audiences</span>
<!--l. 107--><p class="indent" >   A single-person project would require close communication with project advisors,
sponsors, and the general public. We will need literacy in multiple areas: engineering,
biological science, and project management. If the project recruits multiple students,
communication between team members will be not only a core priority, but essential
to a successful outcome.
<!--l. 109--><p class="indent" >   <span 
class="cmti-10">D. an ability to recognize ethical and professional responsibilities in engineering</span>
<span 
class="cmti-10">situations and make informed judgments, which must consider the impact of</span>
<span 
class="cmti-10">engineering solutions in global, economic, environmental, and societal contexts</span>
<!--l. 111--><p class="indent" >   Safety is the largest challenge of the artificial pancreas, because insulin, once
delivered, cannot be removed. Hypoglycemia, caused when too much insulin is
delivered, causes impairment in the best case and death at worst. On the other hand,
hyperglycemia causes both short-term and long-term damage. While there is no
physical risk for this project, minimizing both frequency and severity of
hypoglycemia events will be a core constraint, just as it would be in a real closed-loop
system.
<!--l. 113--><p class="indent" >   <span 
class="cmti-10">E. an ability to function effectively on a team whose members together provide</span>
<span 
class="cmti-10">leadership, create a collaborative and inclusive environment, establish goals, plan</span>
<span 
class="cmti-10">tasks, and meet objectives</span>
<!--l. 115--><p class="indent" >   To accomplish the multiple phases of the project, a significant amount of planning
will be required. Due to the interdisciplinary nature of the project, extensive
collaboration between team members and advisers will be required. If multiple
students are recruited, they will need to work together to succeed, because the team
would need to work across disciplines.
<!--l. 117--><p class="indent" >   <span 
class="cmti-10">F. an ability to develop and conduct appropriate experimentation, analyze and</span>
<span 
class="cmti-10">interpret data, and use engineering judgment to draw conclusions</span>
<!--l. 119--><p class="indent" >   A large amount of data will be produced from the software simulations.
Interpreting this data to inform the design of the controller will be a central challenge
of the project.
<!--l. 121--><p class="indent" >   <span 
class="cmti-10">G. an ability to acquire and apply new knowledge as needed, using appropriate</span>
<span 
class="cmti-10">learning strategies.</span>
<!--l. 123--><p class="indent" >   The AP problem has been studied since the 1970 [1] &#8211; a wide body of research has
been produced about the design of AP controllers in particular.

<!--l. 130--><p class="noindent" >
   <h3 class="sectionHead"><a 
 id="x1-110004"></a>References</h3>
<!--l. 130--><p class="noindent" >
    <dl class="thebibliography"><dt id="X0-Doyle_2014" class="thebibliography">
[1]  </dt><dd 
id="bib-1" class="thebibliography">
    <!--l. 130--><p class="noindent" ><a id="page.10"></a><a 
href="Project_Proposal.html" id="X0-" ></a>FrancisJ.   Doyle   et   al.   &#8220;Closed-Loop   Artificial   Pancreas   Systems:
    Engineering the Algorithms&#8221;. In: <span 
class="cmti-10">Diabetes Care </span>37.5 (2014), pp. 1191&#8211;1197.
    </dd><dt id="X0-Edwin_2002" class="thebibliography">
[2]  </dt><dd 
id="bib-2" class="thebibliography">
    <!--l. 130--><p class="noindent" >Edwin A.M. Gale. &#8220;The Rise of Childhood Type 1 Diabetes in the 20th
    Century&#8221;. In: <span 
class="cmti-10">Diabetes </span>51.12 (2002), pp. 3353&#8211;3361.
    </dd><dt id="X0-Hovorka_2011" class="thebibliography">
[3]  </dt><dd 
id="bib-3" class="thebibliography">
    <!--l. 130--><p class="noindent" >Roman                 Hovorka.                 &#8220;Closed-loop                 insulin
    delivery: from bench to clinical practice&#8221;. In: <span 
class="cmti-10">Nature Reviews Endocrinology</span>
    7.7 (Feb. 2011), pp. 385&#8211;395. <span 
class="cmcsc-10"><span 
class="small-caps">i</span><span 
class="small-caps">s</span><span 
class="small-caps">s</span><span 
class="small-caps">n</span></span>: 1759-5037. <span 
class="cmcsc-10"><span 
class="small-caps">d</span><span 
class="small-caps">o</span><span 
class="small-caps">i</span></span>: 10.1038/nrendo.2011.32.
    <span 
class="cmcsc-10"><span 
class="small-caps">u</span><span 
class="small-caps">r</span><span 
class="small-caps">l</span></span>: <a 
href="http://dx.doi.org/10.1038/nrendo.2011.32" class="url" ><span 
class="cmtt-10">http://dx.doi.org/10.1038/nrendo.2011.32</span></a>.
    </dd><dt id="X0-Man_2014" class="thebibliography">
[4]  </dt><dd 
id="bib-4" class="thebibliography">
    <!--l. 130--><p class="noindent" >Chiara   Dalla   Man   et   al.   &#8220;The   UVA/PADOVA   Type   1   Diabetes
    Simulator&#8221;.  In:  <span 
class="cmti-10">Journal  of  Diabetes  Science  and  Technology  </span>8.1  (Jan.
    2014), pp. 26&#8211;34. <span 
class="cmcsc-10"><span 
class="small-caps">i</span><span 
class="small-caps">s</span><span 
class="small-caps">s</span><span 
class="small-caps">n</span></span>: 1932-2968. <span 
class="cmcsc-10"><span 
class="small-caps">d</span><span 
class="small-caps">o</span><span 
class="small-caps">i</span></span>: 10.1177/1932296813514502. <span 
class="cmcsc-10"><span 
class="small-caps">u</span><span 
class="small-caps">r</span><span 
class="small-caps">l</span></span>:
    <a 
href="http://dx.doi.org/10.1177/1932296813514502" class="url" ><span 
class="cmtt-10">http://dx.doi.org/10.1177/1932296813514502</span></a>.
    </dd><dt id="X0-openAPS" class="thebibliography">
[5]  </dt><dd 
id="bib-5" class="thebibliography">
    <!--l. 130--><p class="noindent" ><span 
class="cmti-10">OpenAPS</span>. 2019. <span 
class="cmcsc-10"><span 
class="small-caps">u</span><span 
class="small-caps">r</span><span 
class="small-caps">l</span></span>: <a 
href="https://openaps.org/" class="url" ><span 
class="cmtt-10">https://openaps.org/</span></a>.
    </dd><dt id="X0-Patterson_2018" class="thebibliography">
[6]  </dt><dd 
id="bib-6" class="thebibliography">
    <!--l. 130--><p class="noindent" >Christopher                                                                               C.
    Patterson et al. &#8220;Trends and cyclical variation in the incidence of childhood
    type 1 diabetes in 26 European centres in the 25 year period 1989&#8211;2013:
    a multicentre prospective registration study&#8221;. In: <span 
class="cmti-10">Diabetologia </span>62.3 (Nov.
    2018), pp. 408&#8211;417. <span 
class="cmcsc-10"><span 
class="small-caps">i</span><span 
class="small-caps">s</span><span 
class="small-caps">s</span><span 
class="small-caps">n</span></span>: 1432-0428. <span 
class="cmcsc-10"><span 
class="small-caps">d</span><span 
class="small-caps">o</span><span 
class="small-caps">i</span></span>: 10.1007/s00125-018-4763-3. <span 
class="cmcsc-10"><span 
class="small-caps">u</span><span 
class="small-caps">r</span><span 
class="small-caps">l</span></span>:
    <a 
href="http://dx.doi.org/10.1007/s00125-018-4763-3" class="url" ><span 
class="cmtt-10">http://dx.doi.org/10.1007/s00125-018-4763-3</span></a>.
    </dd><dt id="X0-simglucose" class="thebibliography">
[7]  </dt><dd 
id="bib-7" class="thebibliography">
    <!--l. 130--><p class="noindent" >Jinyu          Xie.          <span 
class="cmti-10">Simglucose         v0.2.1</span>.          2018.          <span 
class="cmcsc-10"><span 
class="small-caps">u</span><span 
class="small-caps">r</span><span 
class="small-caps">l</span></span>:
    <a 
href="https://github.com/jxx123/simglucose" class="url" ><span 
class="cmtt-10">https://github.com/jxx123/simglucose</span></a>.</dd></dl>
    
</body></html> 



